| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 臺大學術典藏 |
2020-12-02T02:33:14Z |
Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
|
Blackhall F.; Ross Camidge D.; Shaw A.T.; Soria J.-C.; Solomon B.J.; Mok T.; Hirsh V.; J?Nne P.A.; Shi Y.; Pan-Chyr Yang; De Pas T.; Hida T.; De Castro Carpe?O J.; Lanzalone S.; Polli A.; Iyer S.; Reisman A.; Wilner K.D.; Kim D.-W.; Blackhall F.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
|
Lee C.K;Brown C;Gralla R.J;Hirsh V;Thongprasert S;Tsai C.-M;Tan E.H;Ho J.C.-M;Chu D.T;Zaatar A;Osorio Sanchez J.A;Vu V.V;Au J.S.K;Inoue A;Lee S.M;Gebski V;Chih-Hsin Yang; Lee C.K; Brown C; Gralla R.J; Hirsh V; Thongprasert S; Tsai C.-M; Tan E.H; Ho J.C.-M; Chu D.T; Zaatar A; Osorio Sanchez J.A; Vu V.V; Au J.S.K; Inoue A; Lee S.M; Gebski V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Symptom control and quality of life in lux-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
|
Chih-Hsin Yang;Hirsh V;Schuler M;Yamamoto N;O'Byrne K.J;Mok T.S.K;Zazulina V;Shahidi M;Lungershausen J;Massey D;Palmer M;Sequist L.V.; CHIH-HSIN YANG; Hirsh V; Schuler M; Yamamoto N; O'Byrne K.J; Mok T.S.K; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist L.V. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
|
Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
|
Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials
|
Shah R; Märten A; Massey D; Wind S; Wu Y.-L.; Dickgreber N; Okamoto I; Sebastian M; Huang Y; Hirsh V; Lu S; O'Byrne K; Feng J; Wu Y.-L.;Wind S;Massey D;M?rten A;Shah R;Dickgreber N;Okamoto I;Sebastian M;Huang Y;Hirsh V;Lu S;O'Byrne K;Feng J;Yamamoto N;Hu C.-P;Mok T;Geater S.L;Schuler M;Zhou C;Sequist L.V;Chih-Hsin Yang; CHIH-HSIN YANG; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases
|
Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
|
Mok T; Kim M; Paz-Ares L.; Paz-Ares L.;Kim M;Mok T;Chih-Hsin Yang;Boyer M;O'Byrne K;Hirsh V;Zhang L;Tan E.-H;Park K; Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
|
Wu Y.-L.;Shah R;Mok T;Hirsh V;O'Byrne K;Zhou C;Yamamoto N;Sequist L.V;Chih-Hsin Yang;Schuler M; Schuler M; CHIH-HSIN YANG; Sequist L.V; Yamamoto N; Zhou C; O'Byrne K; Hirsh V; Mok T; Shah R; Wu Y.-L. |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6
|
Chih-Hsin Yang;Kim M;Massey D;Gibson N;Hirsh V;O'Byrne K;Yamamoto N;Mok T;Schuler M;Hou M;Li W;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:32Z |
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
|
O?�Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG; Schuler M; Mok T; Yamamoto N; Huang Y; Lu S; Hu C.-P; Feng J; Sequist L.V; Hirsh V; Wu Y.-L; Chih-Hsin Yang;Lungershausen J;M?rten A;Massey D;Zhou C;Geater S.L;O??Byrne K;Yamamoto N;Mok T;Schuler M;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Hirsh V;Wu Y.-L |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
|
Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
|
Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
|
Schuler M;Paz-Ares L;Sequist L.V;Hirsh V;Lee K.H;Wu Y.-L;Lu S;Zhou C;Feng J;Ellis S.H;Samuelsen C.H;Tang W;M?rten A;Ehrnrooth E;Park K;Chih-Hsin Yang; Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-02-25T09:08:37Z |
Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non–Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin
|
Hirsh, V.; Wan, Y.; FANG-JU LIN; Margunato-Debay, S.; Ong, T.J.; Botteman, M.; Langer, C. |
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
|
Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; O'Byrne, K.; Okamoto, I.; Schuler, M.; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Maerten, A.; Wind, S.; Carbone, D. P.; 楊志新 |
| 國立臺灣大學 |
2015 |
Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
|
Wu, Y. -L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. -M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, M.; Hirsh, V.; Yamamoto, N.; O'Byrne, K.; Mok, T.; Massey, D.; Maerten, A.; Yang, J. C. -H.; 楊志新 |
| 臺大學術典藏 |
2015 |
Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
|
Mok T.S.;Smit E.F;Pen? C;Ong T.J;Schmelter T;Sun Y;Ar?n O;Juh?sz E;Novello S;Wu Y.-L;Seto T;Wakelee H.A;Chih-Hsin Yang;De Marinis F;Zhang L;Hirsh V;Paz-Ares L; Paz-Ares L; Hirsh V; Zhang L; De Marinis F; CHIH-HSIN YANG; Wakelee H.A; Seto T; Wu Y.-L; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong T.J; Penã C; Smit E.F; Mok T.S. |
| 臺大學術典藏 |
2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase iib/iii trial (lux-lung 1)
|
Hirsh V;Cadranel J;Cong X.J;Fairclough D;Finnern H.W;Lorence R.M;Miller V.A;Palmer M;Chih-Hsin Yang; Hirsh V; Cadranel J; Cong X.J; Fairclough D; Finnern H.W; Lorence R.M; Miller V.A; Palmer M; CHIH-HSIN YANG |
